Clinical Gastroenterology and Hepatology
Volume 7, Issue 12 , Pages 1314-1321, December 2009

An Association Between Selective Serotonin Reuptake Inhibitor Use and Serious Upper Gastrointestinal Bleeding

  • Michael Dall

      Affiliations

    • Research Unit of Clinical Pharmacology, University of Southern Denmark, Odence, Denmark
    • Department of Medical Gastroenterology, Odence University Hospital, Odence, Denmark
    • Corresponding Author InformationReprint requests Address requests for reprints to: Michael Dall, MD, University of Southern Denmark, Faculty of Health Sciences, Institute of Public Health, Research Unit of Clinical Pharmacology, Winsløwparken 19, 2, DK-5000 Odense C, Denmark. fax: (45) 6591 6089
  • ,
  • Ove B. Schaffalitzky de Muckadell

      Affiliations

    • Department of Medical Gastroenterology, Odence University Hospital, Odence, Denmark
  • ,
  • Annmarie Touborg Lassen

      Affiliations

    • Department of Infectious Medicine, Odense University Hospital, Odense, Denmark
  • ,
  • Jane Møller Hansen

      Affiliations

    • Department of Medical Gastroenterology, Odence University Hospital, Odence, Denmark
  • ,
  • Jesper Hallas

      Affiliations

    • Research Unit of Clinical Pharmacology, University of Southern Denmark, Odence, Denmark

published online 28 August 2009.

Background & Aims

In vitro studies have shown that selective serotonin reuptake inhibitors (SSRIs) inhibit platelet aggregation. It is controversial whether use of SSRIs is a cause of clinically important bleeding; results from observational studies have been equivocal.

Methods

A population-based case-control study was conducted in Denmark. The 3652 cases all had a first discharge diagnosis of serious upper gastrointestinal bleeding (UGB) from 1995 to 2006. Controls (n = 36,502), matched for age and sex, were selected by risk-set sampling. Data on drug exposure and medical history were retrieved from a prescription database and the county's patient register. Confounders were controlled for by conditional logistic regression and the case-crossover design.

Results

The adjusted odds ratio (OR) of UGB among current, recent, and past users of SSRIs was 1.67 (95% confidence interval [CI], 1.46–1.92), 1.88 (95% CI, 1.42–2.5), and 1.22 (95% CI, 1.07–1.39). The adjusted OR for concurrent use of SSRI and nonsteroidal anti-inflammatory drugs (NSAIDs) was 8.0 (95% CI, 4.8–13). The adjusted OR for the concurrent use of NSAID, aspirin, and SSRI was 28 (95% CI, 7.6–103). Of the UGB cases, 377 were current users of SSRI; the adjusted OR for UGB in the case crossover analysis was 2.8 (95% CI, 2.2–3.6). The adjusted OR among users of proton pump inhibitors was 0.96 (95% CI, 0.50–1.82).

Conclusions

Use of SSRI was associated with UGB, consistent with its antiplatelet effects. SSRIs should be prescribed with caution for patients at high risk for UGB.

Abbreviations used in this paper: ASA, acetylsalicylic acid, ATC, anatomical-therapeutic-chemical, CI, confidence interval, COPD, chronic obstructive pulmonary disease, DDD, defined daily dose, FPAS, Funen County Patient Administrative System, ICD- 8, 9, and 10, International Classification of Diseases 8th, 9th, and 10th versions, NNTH, the number of patients needed to be treated for 1 additional patient to be harmed, NSAIDs, nonsteroidal anti-inflammatory drugs, OPED, Odense University Pharmaco-Epidemiological Database, OR, odds ratio, OTC, over-the-counter, PPI, proton pump inhibitor, SSRIs, selective serotonin reuptake inhibitors, TCA, tricyclic antidepressant, UGB, upper gastrointestinal bleeding

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Conflict of interest The authors disclose the following: Dr Hallas has received fees for teaching from AstraZeneca, MSD, and the Danish Association of the Pharmaceutical Industry, and research grants from Novartis, Pfizer, and Nycomed. Dr Schaffalitzky de Muckadell has received fees for teaching from AstraZeneca. The remaining authors disclose no conflicts.

 Funding The University of Southern Denmark and Funen County provided data free of charge.

PII: S1542-3565(09)00800-3

doi:10.1016/j.cgh.2009.08.019

Clinical Gastroenterology and Hepatology
Volume 7, Issue 12 , Pages 1314-1321, December 2009